Advances in the treatment of malignant pleural mesothelioma

Citation
Dh. Sterman et al., Advances in the treatment of malignant pleural mesothelioma, CHEST, 116(2), 1999, pp. 504-520
Citations number
146
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Journal title
CHEST
ISSN journal
00123692 → ACNP
Volume
116
Issue
2
Year of publication
1999
Pages
504 - 520
Database
ISI
SICI code
0012-3692(199908)116:2<504:AITTOM>2.0.ZU;2-C
Abstract
Malignant pleural mesothelioma is a neoplasm that is commonly fatal and for which there are no widely accepted curative approaches. Mesothelioma is un responsive to most chemotherapy and radiotherapy regimens, and it typically recurs even after the most aggressive attempts at surgical resection. Mult imodality approaches have been of some benefit in prolonging survival of ve ry highly selected subgroups of patients, but they have had a relatively sm all impact on the majority of the patients diagnosed with this disease. As the incidence of pleural mesothelioma peaks in the United States and Europe over the next 10 to 20 years, new therapeutic measures will be necessary. This review will discuss the roles of chemotherapy, radiotherapy, surgery, and combined modality approaches in the treatment of pleural mesothelioma, as well as scientific advances made in the past decade that have led to the development of experimental techniques, such as photodynamic therapy, immu notherapy, and gene therapy that are currently undergoing human clinical tr ials, These promising new avenues may modify the therapeutic nihilism that is rampant among clinicians dealing with mesothelioma.